• Users Online: 266
  • Print this page
  • Email this page
ORIGINAL ARTICLE
Year : 2020  |  Volume : 34  |  Issue : 2  |  Page : 72-77

A higher dose (0.8 mg/kg) of ketamine infusion for treatment-resistant depression: An open-label study in Taiwan


1 Department of Psychiatry, Taipei Veterans General Hospital; Division of Psychiatry, Faculty of Medicine, National Yang-Ming University; Institute of Brain Science, National Yang-Ming University, Taipei, Taiwan
2 Department of Psychiatry, Taipei Veterans General Hospital; Institute of Brain Science, National Yang-Ming University, Taipei, Taiwan
3 Department of Psychiatry, Taipei Veterans General Hospital; Division of Psychiatry, Faculty of Medicine, National Yang-Ming University; Institute of Brain Science, National Yang-Ming University; Department of Medical Research, Taipei Veterans General Hospital; Department of Psychiatry, Cheng Hsin General Hospital, Taipei, Taiwan

Correspondence Address:
Cheng- Ta Li
No. 201, Section 2, Shih-Pai Road, Taipei, 112
Taiwan
Tung- Ping Su
No. 201, Section 2, Shih-Pai Road, Taipei, 112
Taiwan
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/TPSY.TPSY_19_20

Rights and Permissions

Objective: Studies of the Caucasian population showed that the treatment response rate of 0.5 mg/kg ketamine infusion is as high as 70% in patients with treatment-resistant depression (TRD). By contrast, our earlier study has found a response rate of about 50% in Taiwanese patients with TRD, with much lower blood levels of ketamine and norketamine. In the current study, we intended to investigate whether a higher (0.8 mg/kg) dose of ketamine infusion can improve the treatment outcome. Methods: An open-label study with six TRD patients was done. Every participant received a single dose (0.8 mg/kg) of ketamine infusion and was followed up for two weeks for depressive symptoms. The blood levels of ketamine and norketamine were also assessed. We combined the data from the current open-label study and our previous randomized double-blind study (0.5 mg/kg, 0.2 mg/kg, and placebo) for further analyses. Results: The treatment response rate in the 0.8 mg/kg group was 66.7% at 240 min after ketamine infusion, which is higher than that in the 0.5 mg/kg group. A generalized estimating equation model indicated a group effect (p < 0.001), a time effect (p < 0.001), and a group*time effect (p < 0.001) for the trajectory of the total depression score among four groups. Ketamine and norketamine levels were dose related (0.8 mg/kg > 0.5 mg/kg > 0.2 mg/kg). Adverse effects, such as a floating feeling and dizziness, did not differ in subjects between the 0.8 mg/kg and 0.5 mg/kg groups. Conclusion: A single higher dose (0.8 mg/kg) of ketamine infusion was a safe and effective treatment strategy for Taiwanese patients with TRD. A 0.8 mg/kg ketamine infusion may achieve optimal blood levels of ketamine and norketamine and may have a superior treatment response in Taiwanese patients.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed80    
    Printed1    
    Emailed0    
    PDF Downloaded18    
    Comments [Add]    

Recommend this journal